<p>Avanos Medical（紐約證券交易所代碼：AVNS - 獲取免費報告）在週一發佈給客户和投資者的研究報告中，被 Zacks Research 的投資分析師從 “強烈賣出” 評級上調至 “持有” 評級，Zacks.com 報道。</p>
<p>獲取 <strong>Avanos Medical</strong> 的提醒：</p>
<p>其他一些股票研究分析師最近也對 AVNS 發佈了報告。Weiss Ratings 在 12 月 22 日的研究報告中重新發布了對 Avanos Medical 股票的 “賣出（d-）” 評級。華爾街 Zen 在 11 月 8 日的研究報告中將 Avanos Medical 的評級從 “買入” 上調至 “強烈買入”。一位研究分析師對該股票給予了 “持有” 評級，另一位則給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “減持”。</p>
<p><strong>查看我們對 Avanos Medical 的最新股票分析</strong></p>
<h2>Avanos Medical 價格表現</h2>
<p>AVNS 股票在週一開盤價為$13.14。Avanos Medical 的 52 周低點為$9.30，52 周高點為$17.69。該公司的速動比率為 1.36，流動比率為 2.38，債務與股本比率為 0.12。該股票的市值為 609.73 百萬美元，市盈率為-1.29，貝塔值為 1.08。該公司的 50 日移動平均線為$11.78，200 日移動平均線為$11.63。</p>
<p>Avanos Medical（紐約證券交易所代碼：AVNS - 獲取免費報告）最近於 11 月 5 日發佈了季度財報。該公司報告本季度每股收益為$0.22，超出分析師的共識預期$0.12，超出幅度為$0.10。該公司本季度的收入為$177.80 百萬，而分析師預期為$164.50 百萬。Avanos Medical 的股本回報率為 6.21%，淨利潤率為-67.00%。與去年同期相比，該公司的收入增長了 4.3%。在去年同期，該公司每股收益為$0.33。Avanos Medical 已將其 2025 財年的指導目標設定為每股收益 0.850-0.950。整體來看，研究分析師預計 Avanos Medical 在當前年度的每股收益為 1.32。</p>
<h2>Avanos Medical 的內部活動</h2>
<p>在其他 Avanos Medical 的新聞中，高級副總裁 Kerr Holbrook 於 11 月 18 日星期二出售了 15,000 股該公司的股票。股票以平均價格$11.00 出售，總價值為$165,000.00。交易完成後，該高級副總裁在公司持有 83,860 股，價值$922,460。這筆交易使他們的持股減少了 15.17%。該交易已在 SEC 的法律文件中披露，相關信息可在 SEC 網站上獲取。目前，2.64% 的股票由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金和其他機構投資者最近買賣了該股票的股份。AQR Capital Management LLC 在第一季度將其在 Avanos Medical 的持股增加了 46.4%。AQR Capital Management LLC 現在擁有 192,864 股該公司的股票，價值$2,700,000，在上個季度又購買了 61,095 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Avanos Medical 的持股增加了 4.3%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 26,955 股該公司的股票，價值$386,000，在上個季度又收購了 1,121 股。Millennium Management LLC 在第一季度將其在 Avanos Medical 的持股增加了 508.3%。Millennium Management LLC 現在擁有 547,740 股該公司的股票，價值$7,849,000，在上個季度又收購了 457,703 股。Empowered Funds LLC 在第一季度將其在 Avanos Medical 的持股增加了 5.4%。Empowered Funds LLC 現在擁有 162,182 股該公司的股票，價值$2,324,000，在上個季度又收購了 8,348 股。最後，UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度將其在 Avanos Medical 的持股增加了 17.1%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 現在擁有 140,810 股該公司的股票，價值$2,018,000，在上個季度又購買了 20,541 股。目前，95.17% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Avanos Medical 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Avanos Medical 是一家全球醫療技術公司，開發和銷售廣泛的醫療設備組合，旨在改善醫院、門診和急性後護理環境中的患者結果。該公司的產品專注於三個核心治療領域——疼痛管理、腸內餵養和呼吸護理——旨在幫助臨牀醫生管理術後疼痛、提供營養支持並協助各種急性和慢性病症患者的呼吸。</p>
<p>在其疼痛管理領域，Avanos 提供非阿片類藥物輸送系統和冷凍鎮痛設備，包括門診輸注泵和冷卻射頻消融平台。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Avanos Medical 更好</li>
<li>美國下一個權力行動從地下開始</li>
<li>您的簽名缺失 - 在為時已晚之前採取行動</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>1933 年的退款：特朗普的重置可能創造即時財富</li>
<li>黃金市場歷史上最大的騙局正在解開</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資$1,000 在 Avanos Medical 嗎？</h2>
<p>在您考慮 Avanos Medical 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Avanos Medical 並不在名單上。</p>
<p>雖然 Avanos Medical 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AVNS

<p>Zacks Research 將 Avanos Medical (NYSE:AVNS) 的評級從 “強烈賣出” 上調至 “持有”。其他分析師的觀點不一，Weiss Ratings 維持 “賣出” 評級，而 Wall Street Zen 則上調至 “強烈買入”。Avanos Medical 的股票開盤價為 13.14 美元，52 周範圍為 9.30 至 17.69 美元。該公司報告了上個季度每股收益為 0.22 美元，超出預期，並預計 2025 財年的每股收益在 0.850 至 0.950 之間。最近的內部交易包括高級副總裁 Kerr Holbrook 出售了 15,000 股股票。95.17% 的股票由機構投資者持有</p>

<p>Avanos Medical (NYSE:AVNS - Get Free Report) was upgraded by investment analysts at Zacks Research from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report issued to clients and investors on Monday,Zacks.com reports.</p>
<div class="lb-trans"><p>Avanos Medical（紐約證券交易所代碼：AVNS - 獲取免費報告）在週一發佈給客户和投資者的研究報告中，被 Zacks Research 的投資分析師從 “強烈賣出” 評級上調至 “持有” 評級，Zacks.com 報道。</p>
</div><p>Get <strong>Avanos Medical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Avanos Medical</strong> 的提醒：</p>
</div><p>A number of other equities research analysts also recently issued reports on AVNS. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Avanos Medical in a research note on Monday, December 22nd. Wall Street Zen raised Avanos Medical from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, November 8th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Reduce&#34;.</p>
<div class="lb-trans"><p>其他一些股票研究分析師最近也對 AVNS 發佈了報告。Weiss Ratings 在 12 月 22 日的研究報告中重新發布了對 Avanos Medical 股票的 “賣出（d-）” 評級。華爾街 Zen 在 11 月 8 日的研究報告中將 Avanos Medical 的評級從 “買入” 上調至 “強烈買入”。一位研究分析師對該股票給予了 “持有” 評級，另一位則給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “減持”。</p>
</div><p><strong>View Our Latest Stock Analysis on Avanos Medical</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Avanos Medical 的最新股票分析</strong></p>
</div><h2>Avanos Medical Price Performance</h2>
<div class="lb-trans"><h2>Avanos Medical 價格表現</h2>
</div><p>AVNS stock opened at $13.14 on Monday. Avanos Medical has a 52-week low of $9.30 and a 52-week high of $17.69. The company has a quick ratio of 1.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.12. The stock has a market cap of $609.73 million, a price-to-earnings ratio of -1.29 and a beta of 1.08. The business has a fifty day moving average of $11.78 and a two-hundred day moving average of $11.63.</p>
<div class="lb-trans"><p>AVNS 股票在週一開盤價為$13.14。Avanos Medical 的 52 周低點為$9.30，52 周高點為$17.69。該公司的速動比率為 1.36，流動比率為 2.38，債務與股本比率為 0.12。該股票的市值為 609.73 百萬美元，市盈率為-1.29，貝塔值為 1.08。該公司的 50 日移動平均線為$11.78，200 日移動平均線為$11.63。</p>
</div><p>Avanos Medical (NYSE:AVNS - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.10. The business had revenue of $177.80 million during the quarter, compared to analysts' expectations of $164.50 million. Avanos Medical had a positive return on equity of 6.21% and a negative net margin of 67.00%.The company's revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.33 EPS. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. As a group, research analysts anticipate that Avanos Medical will post 1.32 earnings per share for the current year.</p>
<div class="lb-trans"><p>Avanos Medical（紐約證券交易所代碼：AVNS - 獲取免費報告）最近於 11 月 5 日發佈了季度財報。該公司報告本季度每股收益為$0.22，超出分析師的共識預期$0.12，超出幅度為$0.10。該公司本季度的收入為$177.80 百萬，而分析師預期為$164.50 百萬。Avanos Medical 的股本回報率為 6.21%，淨利潤率為-67.00%。與去年同期相比，該公司的收入增長了 4.3%。在去年同期，該公司每股收益為$0.33。Avanos Medical 已將其 2025 財年的指導目標設定為每股收益 0.850-0.950。整體來看，研究分析師預計 Avanos Medical 在當前年度的每股收益為 1.32。</p>
</div><h2>Insider Activity at Avanos Medical</h2>
<div class="lb-trans"><h2>Avanos Medical 的內部活動</h2>
</div><p>In other Avanos Medical news, SVP Kerr Holbrook sold 15,000 shares of the business's stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $11.00, for a total value of $165,000.00. Following the completion of the transaction, the senior vice president owned 83,860 shares in the company, valued at $922,460. The trade was a 15.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 2.64% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Avanos Medical 的新聞中，高級副總裁 Kerr Holbrook 於 11 月 18 日星期二出售了 15,000 股該公司的股票。股票以平均價格$11.00 出售，總價值為$165,000.00。交易完成後，該高級副總裁在公司持有 83,860 股，價值$922,460。這筆交易使他們的持股減少了 15.17%。該交易已在 SEC 的法律文件中披露，相關信息可在 SEC 網站上獲取。目前，2.64% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC increased its holdings in Avanos Medical by 46.4% in the first quarter. AQR Capital Management LLC now owns 192,864 shares of the company's stock valued at $2,700,000 after buying an additional 61,095 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Avanos Medical by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company's stock valued at $386,000 after acquiring an additional 1,121 shares during the last quarter. Millennium Management LLC raised its position in shares of Avanos Medical by 508.3% during the 1st quarter. Millennium Management LLC now owns 547,740 shares of the company's stock worth $7,849,000 after acquiring an additional 457,703 shares in the last quarter. Empowered Funds LLC raised its position in shares of Avanos Medical by 5.4% during the 1st quarter. Empowered Funds LLC now owns 162,182 shares of the company's stock worth $2,324,000 after acquiring an additional 8,348 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Avanos Medical by 17.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company's stock worth $2,018,000 after purchasing an additional 20,541 shares during the last quarter. 95.17% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近買賣了該股票的股份。AQR Capital Management LLC 在第一季度將其在 Avanos Medical 的持股增加了 46.4%。AQR Capital Management LLC 現在擁有 192,864 股該公司的股票，價值$2,700,000，在上個季度又購買了 61,095 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Avanos Medical 的持股增加了 4.3%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 26,955 股該公司的股票，價值$386,000，在上個季度又收購了 1,121 股。Millennium Management LLC 在第一季度將其在 Avanos Medical 的持股增加了 508.3%。Millennium Management LLC 現在擁有 547,740 股該公司的股票，價值$7,849,000，在上個季度又收購了 457,703 股。Empowered Funds LLC 在第一季度將其在 Avanos Medical 的持股增加了 5.4%。Empowered Funds LLC 現在擁有 162,182 股該公司的股票，價值$2,324,000，在上個季度又收購了 8,348 股。最後，UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度將其在 Avanos Medical 的持股增加了 17.1%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 現在擁有 140,810 股該公司的股票，價值$2,018,000，在上個季度又購買了 20,541 股。目前，95.17% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Avanos Medical Company Profile</h2>
<div class="lb-trans"><h2>Avanos Medical 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company's products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.</p>
<div class="lb-trans"><p>Avanos Medical 是一家全球醫療技術公司，開發和銷售廣泛的醫療設備組合，旨在改善醫院、門診和急性後護理環境中的患者結果。該公司的產品專注於三個核心治療領域——疼痛管理、腸內餵養和呼吸護理——旨在幫助臨牀醫生管理術後疼痛、提供營養支持並協助各種急性和慢性病症患者的呼吸。</p>
</div><p>In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.</p>
<div class="lb-trans"><p>在其疼痛管理領域，Avanos 提供非阿片類藥物輸送系統和冷凍鎮痛設備，包括門診輸注泵和冷卻射頻消融平台。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Avanos Medical</li>
<li>America's Next Power Move Starts Underground</li>
<li>Your Signature Is Missing – Act Before It’s Too Late</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li>
<li>The biggest scam in the history of gold markets is unwinding</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Avanos Medical 更好</li>
<li>美國下一個權力行動從地下開始</li>
<li>您的簽名缺失 - 在為時已晚之前採取行動</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>1933 年的退款：特朗普的重置可能創造即時財富</li>
<li>黃金市場歷史上最大的騙局正在解開</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Avanos Medical Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資$1,000 在 Avanos Medical 嗎？</h2>
</div><p>Before you consider Avanos Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Avanos Medical 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Avanos Medical 並不在名單上。</p>
</div><p>While Avanos Medical currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Avanos Medical 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Avanos Medical（NYSE:AVNS）在 Zacks Research 的評級被上調至 “持有”